NECTID ANNOUNCES INITIATION OF THE
DEVELOPMENT OF ITS FXR PLATFORM- NFX-21 FOR NONALCOHOLIC FATTY LIVER DISEASE (NALFD)
Princeton, NJ – February 18, 2014
Nectid, Inc. (www.nectid.com
), a Princeton based pharmaceutical product development company focused on discovering and developing novel platform technologies, announced initiating clinical development of FXR Platform for Non-Alcoholic Fatty Liver Disease indication in the United States.
The farnesoid X receptor (FXR) is a key regulator of bile acid (BA) metabolism in the liver. Additionally, FXR regulates lipid metabolism, insulin sensitivity, and energy homeostasis and its activation lowers plasma and liver triglycerides. Nectid’s FXR platform comprises Medium Chain Triglycerides (MCT) and Docosahexaenoic Acid (DHA), which have demonstrated safe use in refractory epilepsy and cardiovascular indications for decades. The combination has been found to significantly improve hepatocyte lipid metabolism in healthy volunteers.
Nectid’s founder/CEO Ram Sesha has said, “This is a repurposing program of known and safe ingredients to provide several key unmet needs including non alcoholic fatty liver (NAFLD), Primary Biliary Cirrhosis and Portal Hypertension etc. It is a novel use discovery for this combination. The prevalence of NAFLD in the general population is up to 30%; however, it is much higher among individuals with type 2 diabetes mellitus and obesity, 2 key features of metabolic syndrome. NAFLD is strongly associated with dyslipidemia, particularly hypertriglyceridemia, which may contribute to the increased risk of cardiovascular disease in these subjects. Nectid’s FXR platform is likely have potential applications in neurological indications. Nectid plans to develop this through FDA approval while it is in licensing discussion with interested parties for Non-US markets”.
), is a Princeton based drug-discovery company that focuses on repurposing known drugs for neurological and metabolic disorders. Nectid has licensed 19 patents in the last three years to branded pharmaceutical companies. Nectid raised a Series A funding recently from Singapore based Agnus Global Fund.